On the basis of data collected from 320 participants (152 men and 168 women), 4 significant findings were obtained: (a) The form of message claims in CSR advertisements affects advertising preference and advertising credibility, (b) levels of advertising skepticism affect advertising preference and advertising credibility, (c) consumers with high advertising skepticism exhibit advertising skepticism toward CSR advertisements with single-message claims, (d) consumers with low advertising skepticism exhibit preference for CSR advertisements with multiple-message claims. low), to elucidate how these influence advertising preferences and advertising credibility. multiple message), and levels of advertising skepticism (high vs. We adopted a 2 × 2 mixed experimental design to control for form of corporate social responsibility (CSR), advertising message claims (single message vs. This time on therapy advantage also indicated that pts on nab-P were less likely to D/C due to AEs, more likely to stay on therapy, and more likely to be candidates for subsequent therapies. Conclusions: Women treated for mBC stayed on nab-P therapy 50% longer than with other taxanes.

Median time to D/C associated with AEs, neutropenia, death/disenrollment or subsequent therapy were significantly longer for nab-P compared with D or P (p<0.05). Median time to D/C was 85 days for each of D and P, and 127 days for nab-P (p<0.05). Similarly, a higher proportion of pts on nab-P (51.2%) initiated subsequent therapy at D/C of taxane vs D (31%) or P (37.3% p<0.01 for both comparisons). A higher proportion of pts on nab-P (12.3%) continued on therapy until death/disenrollment vs D (8.9%, p 0.046) or P (7.1%, p 0.023). A higher proportion of pts on D (29.4%) and P (17.5%) had D/C due to neutropenia vs nab-P (6.9%, p<0.001 for both comparisons). The most common reason for D/C in all pts was AEs (37.8%), initiation of subsequent therapy (34.4%), and death or disenrollment (8.4%). Results: 4,503 pts with mBC were included (2,599 received D 1,643 received P, and 261 received nab-P). Death or disenrollment from the insurance plan within 90 days and initiation of subsequent therapy within 60 days after D/C were considered temporally associated with D/C. AE within 35-days after D/C were considered taxane-associated. Drug D/C was defined as no taxane administration for 35 days.

Control variables were age, use of prior or concurrent chemo, and comorbidity score. Logistic regression and Cox-proportional hazards models were used to compare rates of D/C and time to D/C, respectively. Methods: Women receiving >1 dose of either paclitaxel (P), docetaxel (D), or nab-paclitaxel (nab-P) between 2006-2009 were identified by ICD-9 codes indicative of mBC from a commercial payer claims database. This study evaluated differences in time to discontinuation (D/C) between taxanes overall and by specific events associated with D/C (i.e., death, adverse events (AE), subsequent therapy). 158 Background: Taxanes in metastatic breast cancer (mBC) have demonstrated clinical benefits but have different toxicity profiles.

Reverend barbour hb and k soundbyte